Which Peptide Business Should You Actually Build?

Start With the Simplest Possible Distinction

A genuine research-product business is fundamentally a commerce business. A telehealth business is fundamentally a healthcare delivery business with a commerce layer around it.

That difference changes almost everything downstream. In the first model, you’re primarily designing a product company. In the second, you’re orchestrating a healthcare experience.

Which is why the useful question isn’t which market is hotter.

The better question is: which machine do you actually want to own?

Once you see that, a lot of the confusion disappears.

Telehealth Is Not “Selling Peptides Online”

This is probably the biggest misconception we’d want to remove.

Imagine somebody launches a telehealth weight-management company. A patient arrives because they’re interested in treatment. They complete an intake. A qualified healthcare provider evaluates them. If treatment is medically appropriate, the provider may prescribe a medication. A pharmacy dispenses it, and there may then be ongoing clinical care.

The entrepreneur isn’t supposed to be sitting behind the website deciding who gets tirzepatide.

• The clinician makes clinical decisions.
• The pharmacy performs the pharmacy function.
• The telehealth company coordinates the experience around those regulated functions.

That distinction creates both complexity and opportunity. A well-built telehealth company can create a remarkably convenient consumer experience around something that historically involved calling a doctor’s office, waiting for an appointment, traveling to a clinic, visiting a pharmacy and coordinating multiple parties. Technology can compress that journey.

That’s why telehealth can be such a powerful business model. But it also means you’re not simply building ecommerce. You’re building infrastructure around healthcare.

The Patient’s Location Suddenly Matters

This is where telehealth becomes particularly interesting in the United States. A founder might think: if the consultation happens on the internet, why does geography matter?

Because healthcare licensure is still heavily state-based. HHS explains that the ability to deliver health care services across state lines varies by state. Depending on the circumstances, providers may need a full state license, qualify through reciprocity or a licensure compact, use a temporary-practice provision, or register under a state’s telehealth pathway.

The internet may be national. Medical practice isn’t automatically national.

A physician sitting in Florida having a video consultation with someone physically located in another state can implicate the rules of the patient’s state. That creates an entirely different scaling problem.

A research ecommerce company asks “can we ship there?” A telehealth company also has to ask “can our clinical network appropriately serve a patient there?”

So when you see a telehealth company advertising nationwide access, there can be substantial clinical and licensing infrastructure behind that simple statement. That’s valuable to understand as an entrepreneur, because it reveals where part of the moat can come from.

Telehealth Is Really a Network Business

At first glance, a telehealth company looks like a website. In reality, a strong telehealth company can be a network connecting multiple participants: patients, technology, licensed providers, pharmacy infrastructure, medication fulfillment and the ongoing patient experience.

The value isn’t necessarily any individual piece. It’s the coordination. The customer experiences one brand; behind that brand may sit an entire ecosystem — with much greater regulatory and clinical responsibility than an ordinary marketplace.

A Research Peptide Brand Is a Different Kind of Opportunity

Now compare that with a legitimate research-focused product company. The business is much closer to specialized ecommerce and distribution. You’re thinking about product selection, supply, appropriate analytical testing, documentation, packaging, inventory, branding, commerce, payments, fulfillment, customer service, B2B accounts and customer acquisition.

The core economic unit is much more familiar to anyone who has operated ecommerce. You acquire a customer. They purchase products. You earn gross margin. Some customers purchase again. Some purchase multiple products. You may also develop wholesale or B2B relationships.

The machine can therefore become: products, distribution, brand, repeat purchasing and B2B. That is much closer to the model we’ve built with Retabionix — and commercially, there’s a lot we like about it. We went through how those pieces fit together, and how a single infrastructure layer can serve more than one revenue stream, in Why a Supplier and a Website Aren’t Enough.

The Owner Doesn’t Need to Build a Healthcare Organization

This is an important distinction for somebody considering both models. If you’re building a genuine research-product company, you’re not trying to create a nationwide network of clinicians to prescribe your research products to consumers. You’re building a product business.

That doesn’t make it regulation-free, and the distinction has to be genuine rather than something that exists only in a footer disclaimer. FDA has been particularly active here in 2026.

In a warning letter issued to Royal Peptides LLC on 24 August, FDA wrote:

“Despite statements on your product labeling marketing your products ‘for research use only’ and ‘not for human or animal consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use. In addition to the cited drug claims, you market bacteriostatic water alongside a ‘peptide guide’ and ‘peptide calculator,’ resources that collectively provide the means to prepare an injectable drug for human administration.” US Food and Drug Administration, 24 August 2026

FDA made a similar determination involving Gram Peptides earlier this year.

So the takeaway isn’t “put research use only on the bottle and you’re done.” It’s actually a much better business principle:

Build the company you claim to operate.

If you’re operating a research-focused business, its positioning, products, content, customer journey and marketing should be designed consistently with that model, with appropriate professional guidance. That’s more robust than trying to make one disclaimer carry the weight of the entire company.

The Revenue Engines Are Different Too

Imagine two companies each doing $500,000 per month. The number on the dashboard might look identical. The businesses underneath it could be completely different.

A telehealth company’s economics may include patient acquisition, provider costs, pharmacy relationships, technology, patient support, prescription-related workflows and potentially recurring membership or care-program revenue. A research ecommerce business might instead have product costs, testing, packaging, warehousing, payment fees, fulfillment, customer acquisition and support.

Revenue tells you how much money passed through the front door. It doesn’t tell you what kind of house is behind it.

Telehealth Has an Attractive Feature Ecommerce Founders Notice Immediately

Recurring revenue. A telehealth program may involve an ongoing patient relationship rather than a one-off transaction. When appropriate treatment continues over time, the business can potentially have recurring economics around the patient relationship. That’s commercially attractive: customer acquisition becomes easier to justify when the relationship has meaningful lifetime value.

But recurring revenue doesn’t appear magically because you put “$299/month” on a pricing page. You have to earn retention. Patients need appropriate ongoing care. The provider network has to work. Pharmacy fulfillment has to work. Customer service has to work. The economics need to work.

And medical appropriateness comes before commercial retention

That’s another way healthcare differs from ordinary subscription ecommerce. If Netflix wants you to stay subscribed forever, that’s generally excellent for Netflix. A healthcare company can’t approach clinical decisions with the assumption that keeping every patient on every treatment indefinitely is the commercial objective.

The clinical function needs its own integrity.

Research Ecommerce Creates Recurring Economics a Different Way

A product company doesn’t necessarily need a formal subscription to develop valuable repeat revenue. Repeat purchasing can emerge naturally from customer behavior. This is one reason we pay close attention to cohorts rather than simply first-order revenue.

At first glance, Campaign A wins. Six months later the conclusion changes entirely. This is why mature ecommerce operators stop looking only at cost per acquisition versus first-order revenue, and begin looking at cost per acquisition versus contribution margin over the customer lifetime.

That is a much more sophisticated growth model. And once you have enough transaction history, you can start making those decisions using your own data rather than industry guesses.

One Business Is More Clinical. One Is More Commercial.

This is probably the cleanest way to explain the difference.

Both require serious execution. But they reward somewhat different founder strengths. Someone coming from ecommerce, branding, distribution or direct response may naturally understand the second machine more quickly. Someone with healthcare infrastructure, provider relationships or clinical operations experience may find the first particularly interesting.

The GLP-1 Boom Made the Difference Easier to Miss

There is a historical reason people confuse these businesses. GLP-1 demand exploded. Suddenly consumers were seeing semaglutide and tirzepatide everywhere. Telehealth companies entered aggressively. Compounding became part of the public conversation. Research peptide companies expanded. Entrepreneurs saw opportunity. And all of those businesses became mentally grouped into “the peptide market.”

But the regulatory environment around compounded GLP-1s has changed substantially. FDA says compounded drugs are not FDA-approved, meaning FDA does not review them for safety, effectiveness or quality before marketing in the same way it reviews approved drugs. In March 2026, FDA announced warning letters to 30 telehealth companies over allegedly false or misleading claims concerning compounded GLP-1 products.

FDA has also continued changing the framework surrounding compounding. In April 2026, it proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list after concluding it had not identified a clinical need for outsourcing facilities to compound them from bulk substances.

That proposal is particularly useful for entrepreneurs to understand, because it demonstrates something bigger:

A business built around healthcare cannot assume today’s drug-access environment will remain frozen forever.

The regulatory environment is part of the business environment.

This Doesn’t Make Telehealth a Bad Business

Quite the opposite. We think this is where sophisticated entrepreneurs separate themselves from opportunity chasers.

An opportunity chaser asks “what’s the easiest thing I can sell right now?” An operator asks “what infrastructure would I be comfortable owning if this market matures?”

Telehealth can be a substantial, sophisticated business when built properly. You can create a recognizable healthcare brand, develop patient relationships, build clinical infrastructure and technology, develop acquisition systems, build pharmacy relationships and potentially expand into additional services. The company can become much larger than a single medication.

But that’s exactly the point. The valuable telehealth company isn’t simply “a website selling GLP-1.” It’s a healthcare platform. And the valuable research peptide company isn’t simply “a website selling vials.” It’s a product, distribution and brand platform.

Both become more interesting when you stop defining them by the thing sitting on the product page.

The Marketing Is Different as Well

This is an area where new founders can make expensive assumptions.

In telehealth, you’re marketing healthcare services and potentially prescription-drug access. FDA has been actively scrutinizing how telehealth companies describe compounded products — among other things, warning against misleadingly presenting compounded products as equivalent to FDA-approved drugs, or implying that compounded drugs themselves are FDA-approved.

Research-product marketing presents a different challenge: the business needs to avoid creating an intended-use story inconsistent with the research model.

And across health-related advertising more generally, the FTC evaluates both express and implied claims and considers the overall “net impression” an advertisement creates. Objective health claims require appropriate substantiation.

There’s a positive lesson in this. It forces better marketers to find differentiation somewhere other than increasingly aggressive health promises — brand, trust, transparency, service, education, customer experience, commercial positioning, product selection and authority. Those are much more durable competitive advantages anyway.

So Which Business Would We Build?

This is where our own experience obviously influences our answer. We built Retabionix as a peptide product business. It generated approximately $500,000 in its first 45 days and today does approximately $500,000 per month across B2B and B2C revenue.

What we like about the model isn’t simply that it has generated revenue. We like the underlying commercial architecture: a brand, products, supply relationships, infrastructure, customers, transaction data, B2B relationships, multiple routes to market, operational knowledge — and an asset capable of becoming more valuable as those things accumulate.

That’s the kind of business we understand deeply because we’ve actually operated it. The full story is in the Retabionix case study.

It’s also why PeptiCEOs focuses on helping entrepreneurs build their own peptide brands, rather than pretending every opportunity inside the broader peptide economy is the same.

The Question Isn’t “How Do I Get Into Peptides?”

If we were sitting across the table from someone considering this industry, we’d change the question. Don’t start with “how do I get into peptides?” Start with “what kind of company do I want to own?”

• Do you want to coordinate clinical care?
• Do you want to build a product brand?
• Do you want B2B relationships?
• Do you want direct-to-consumer ecommerce?
• Do you have healthcare experience?
• Do you have ecommerce experience?
• How much operational complexity do you want?
• Where do you believe your competitive advantage can come from?
• What do you want the company to look like three years from now?

Those questions lead to much better decisions than simply asking which peptide is trending this month. Because trends change. Good businesses outlive the trend that introduced you to the market.

If the Product-Brand Model Is the One You Want

If the product-brand model is what interests you, this is the exact world we’ve spent our time learning. And PeptiCEOs exists because we don’t think the best way to transfer that experience is by giving you another course.

We build the business for you. Our team takes the infrastructure, relationships and operating experience we’ve developed through building and operating in this market and applies it to your own brand and business build within our scope.

You own the company. You make the important decisions. And you remain responsible for your business and for obtaining appropriate professional advice where required. But you aren’t trying to reverse-engineer an unfamiliar industry from YouTube videos, vendor websites and fifty open browser tabs.